ElotuzumabFirst report of interstitial lung disease: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2018年 / 1708卷 / 1期

关键词：

D O I：

10.1007/s40278-018-48234-y

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：141 / 141

相关论文

共 50 条

[1] AlectinibFirst report of interstitial lung disease: case report
Reactions Weekly, 2015, 1541 (1) : 15 - 15
[2] VandetanibFirst report of diffuse interstitial lung disease: case report
Reactions Weekly, 2012, 1407 (1) : 39 - 39
[3] AxitinibExacerbation of interstitial lung disease: case report
Reactions Weekly, 2019, 1741 (1) : 49 - 49
[4] CrizotinibExacerbation of interstitial lung disease : case report
Reactions Weekly, 2021, 1886 (1) : 145 - 145
[5] AntineoplasticsFatal interstitial lung disease: case report
Reactions Weekly, 2011, 1347 (1) : 10 - 10
[6] NilotinibIrreversible interstitial lung disease: case report
Reactions Weekly, 2022, 1899 (1) : 302 - 302
[7] CrizotinibAcute interstitial lung disease: case report
Reactions Weekly, 2014, 1501 (1) : 16 - 16
[8] AfatinibFatal interstitial lung disease: case report
Reactions Weekly, 2018, 1712 (1) : 32 - 32
[9] OsimertinibAcute interstitial lung disease: case report
Reactions Weekly, 2016, 1608 (1) : 215 - 215
[10] Daratumumab Interstitial lung disease: case report
Reactions Weekly, 2023, 1979 (1) : 145 - 145

← 1 2 3 4 5 →